TN2011000370A1 - Alkylamine-substituted dicyanopyridine and amino acid ester prodrugs thereof - Google Patents

Alkylamine-substituted dicyanopyridine and amino acid ester prodrugs thereof

Info

Publication number: TN2011000370A1
Authority: TN; Tunisia
Prior art keywords: amino acid; acid ester; alkylamine; ester prodrugs; dicyanopyridine
Prior art date: 2009-01-29

Application number

TN2011000370A

Other languages

English (en)

Inventor

Alexandros Vakalopoulos

Daniel Meibom

Barbara Albrecht-Kupper

Katja Zimmermann

Joerg Keldenich

Hans-Georg Lerchen

Peter Nell

Frank Sussmeier

Ursula Krenz

Original Assignee

Bayer Ip Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-01-29

Filing date

2011-07-27

Publication date

2013-03-27

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41724154&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2011000370(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2011-07-27 Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh

2013-03-27 Publication of TN2011000370A1 publication Critical patent/TN2011000370A1/fr

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06086—Dipeptides with the first amino acid being basic
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
- C07K5/06147—Dipeptides with the first amino acid being heterocyclic and His-amino acid; Derivatives thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
- C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Diabetes (AREA)
Cardiology (AREA)
Epidemiology (AREA)
Hematology (AREA)
Heart & Thoracic Surgery (AREA)
Obesity (AREA)
Crystallography & Structural Chemistry (AREA)
Endocrinology (AREA)
Urology & Nephrology (AREA)
Child & Adolescent Psychology (AREA)
Vascular Medicine (AREA)
Emergency Medicine (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)
Pyridine Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Peptides Or Proteins (AREA)

TN2011000370A 2009-01-29 2011-07-27 Alkylamine-substituted dicyanopyridine and amino acid ester prodrugs thereof TN2011000370A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE102009006602A DE102009006602A1 (de)	2009-01-29	2009-01-29	Alkylamino-substituierte Dicyanopyridine und deren Aminosäureester-Prodrugs
PCT/EP2010/000262 WO2010086101A1 (fr)	2009-01-29	2010-01-19	Dicyanopyridine à substitution alkylamino et ses promédicaments d'ester d'acide aminé

Publications (1)

Publication Number	Publication Date
TN2011000370A1 true TN2011000370A1 (en)	2013-03-27

Family

ID=41724154

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TN2011000370A TN2011000370A1 (en)	2009-01-29	2011-07-27	Alkylamine-substituted dicyanopyridine and amino acid ester prodrugs thereof

Country Status (42)

Country	Link
US (3)	US8420825B2 (fr)
EP (2)	EP2391620B1 (fr)
JP (2)	JP5693469B2 (fr)
KR (2)	KR101717305B1 (fr)
CN (2)	CN104844687B (fr)
AR (1)	AR075050A1 (fr)
AU (1)	AU2010207786B2 (fr)
BR (1)	BRPI1007308A2 (fr)
CA (2)	CA2962039A1 (fr)
CO (1)	CO6400193A2 (fr)
CR (1)	CR20110407A (fr)
CU (1)	CU24037B1 (fr)
CY (2)	CY1115403T1 (fr)
DE (1)	DE102009006602A1 (fr)
DK (2)	DK2391620T3 (fr)
DO (1)	DOP2011000243A (fr)
EA (1)	EA019275B1 (fr)
EC (1)	ECSP11011235A (fr)
ES (2)	ES2614702T3 (fr)
GT (1)	GT201100205A (fr)
HK (1)	HK1211308A1 (fr)
HN (1)	HN2011002037A (fr)
HR (2)	HRP20140714T1 (fr)
HU (1)	HUE032008T2 (fr)
IL (1)	IL214019A0 (fr)
JO (1)	JO2927B1 (fr)
LT (1)	LT2743270T (fr)
MA (1)	MA33000B1 (fr)
MX (1)	MX2011007800A (fr)
MY (1)	MY156434A (fr)
NZ (1)	NZ594267A (fr)
PE (2)	PE20120430A1 (fr)
PL (2)	PL2391620T3 (fr)
PT (2)	PT2391620E (fr)
RS (1)	RS53448B (fr)
SG (1)	SG172968A1 (fr)
SI (2)	SI2391620T1 (fr)
TN (1)	TN2011000370A1 (fr)
TW (2)	TWI457126B (fr)
UA (1)	UA104613C2 (fr)
UY (1)	UY32393A (fr)
WO (1)	WO2010086101A1 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE102004042607A1 (de)	2004-09-03	2006-03-09	Bayer Healthcare Ag	Substituierte Phenylaminothiazole und ihre Verwendung
DE102006042143A1 (de)	2006-09-08	2008-03-27	Bayer Healthcare Aktiengesellschaft	Neue substituierte Bipyridin-Derivate und ihre Verwendung
DE102006056740A1 (de)	2006-12-01	2008-06-05	Bayer Healthcare Ag	Cyclisch substituierte 3,5-Dicyano-2-thiopyridine und ihre Verwendung
DE102006056739A1 (de)	2006-12-01	2008-06-05	Bayer Healthcare Ag	Substituierte 4-Amino-3,5-dicyano-2-thiopyridine und ihre Verwendung
DE102007035367A1 (de)	2007-07-27	2009-01-29	Bayer Healthcare Ag	Substituierte Aryloxazole und ihre Verwendung
DE102007036076A1 (de) *	2007-08-01	2009-02-05	Bayer Healthcare Aktiengesellschaft	Dipeptoid-Produgs und ihre Verwendung
DE102008013587A1 (de)	2008-03-11	2009-09-17	Bayer Schering Pharma Aktiengesellschaft	Heteroaryl-substituierte Dicyanopyridine und ihre Verwendung
JP2011520997A (ja)	2008-05-29	2011-07-21	バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト	２−アルコキシ置換ジシアノピリジン類およびそれらの使用
DE102008062567A1 (de)	2008-12-16	2010-06-17	Bayer Schering Pharma Aktiengesellschaft	Dipeptoid-Prodrugs und ihre Verwendung
DE102009006602A1 (de) *	2009-01-29	2010-08-05	Bayer Schering Pharma Aktiengesellschaft	Alkylamino-substituierte Dicyanopyridine und deren Aminosäureester-Prodrugs
DE102010030688A1 (de)	2010-06-30	2012-01-05	Bayer Schering Pharma Aktiengesellschaft	Substituierte Dicyanopyridine und ihre Verwendung
US20120058983A1 (en) *	2010-09-02	2012-03-08	Bayer Pharma Aktiengesellschaft	Adenosine A1 agonists for the treatment of glaucoma and ocular hypertension
CA2895875A1 (fr)	2012-12-21	2014-06-26	Sanofi	Derives de l'exendine 4
WO2015086561A1 (fr) *	2013-12-12	2015-06-18	Bayer Pharma Aktiengesellschaft	Agonistes a1 de l'adénosine utilisés comme médicaments contre les maladies des reins
US9318574B2 (en)	2014-06-18	2016-04-19	International Business Machines Corporation	Method and structure for enabling high aspect ratio sacrificial gates
TN2017000466A1 (en) *	2015-05-06	2019-04-12	Bayer Pharma AG	Process for the preparation of 2-{4-[2-({[2-(4-chlorophenyl)-1,3-thiazol-4-yl]methyl}sulfanyl)-3,5-dicyano-6-(pyrrolidin-1-yl)pyridin-4-yl]phenoxy}ethyl-l-alanyl-l-alaninate monohydrochloride
WO2017137528A1 (fr)	2016-02-12	2017-08-17	Charité - Universitätsmedizin Berlin	Agoniste du récepteur a1 de l'adénosine pour utilisation dans le traitement de l'état de mal épileptique
WO2018108884A1 (fr)	2016-12-16	2018-06-21	Bayer Pharma Aktiengesellschaft	Formulation de comprimés pharmaceutiques
WO2018153899A1 (fr)	2017-02-22	2018-08-30	Bayer Pharma Aktiengesellschaft	Agonistes partiels sélectifs du récepteur a1 de l'adénosine en combinaison avec des stimulateurs et/ou activateurs de la guanylate cyclase soluble (sgc)
WO2018153895A1 (fr)	2017-02-22	2018-08-30	Bayer Pharma Aktiengesellschaft	Agonistes partiels sélectifs du récepteur a1 de l'adénosine en combinaison avec un inhibiteur de l'endopeptidase neutre et/ou un antagoniste du récepteur de l'angiotensine ii
WO2018153900A1 (fr) *	2017-02-22	2018-08-30	Bayer Aktiengesellschaft	Agonistes partiels sélectifs du récepteur a1 de l'adénosine en combinaison avec des inhibiteurs de sglt-2
WO2018153897A1 (fr)	2017-02-22	2018-08-30	Bayer Pharma Aktiengesellschaft	Agonistes partiels sélectifs du récepteur a1 de l'adénosine en combinaison avec des inhibiteurs des canaux hcn
WO2018153898A1 (fr) *	2017-02-22	2018-08-30	Bayer Pharma Aktiengesellschaft	Agonistes partiels sélectifs du récepteur a1 de l'adénosine en combinaison avec des antagonistes du récepteur des minéralocorticoïdes
WO2018219804A1 (fr) *	2017-06-02	2018-12-06	Bayer Pharma Aktiengesellschaft	Systèmes d'administration de médicaments auto-émulsifiants
WO2018219801A1 (fr)	2017-06-02	2018-12-06	Bayer Pharma Aktiengesellschaft	Extrudats à libération immédiate
WO2019180072A1 (fr)	2018-03-22	2019-09-26	Bayer Pharma Aktiengesellschaft	Composition pharmaceutique parentérale consistant en du bialanate de néladénoson
US12029718B2 (en)	2021-11-09	2024-07-09	Cct Sciences, Llc	Process for production of essentially pure delta-9-tetrahydrocannabinol

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4052510A (en)	1974-12-18	1977-10-04	Sandoz, Inc.	4-alkyl-2,6-di(secondary or tertiary alkylamino) pyridines, compositions thereof and methods for treating diabetes and obesity
TW299333B (fr)	1992-12-29	1997-03-01	Takeda Pharm Industry Co Ltd
DK0765327T3 (da)	1994-06-16	1999-11-29	Pfizer	Pyrazolo- og pyrrolopyridiner
DE4430638A1 (de)	1994-08-29	1996-03-07	Bayer Ag	Verwendung von substituierten 4-Phenyl-6-amino-nicotinsäurederivaten als Arzneimittel
JPH09132529A (ja)	1995-11-09	1997-05-20	Ono Pharmaceut Co Ltd	一酸化窒素合成酵素阻害剤
EP0876379A1 (fr)	1996-01-17	1998-11-11	Novo Nordisk A/S	Derives de 1,2,4-thiadiazine fusionnee et de 1,4-thiazine fusionnee, leur preparation et utilisation
ATE548351T1 (de)	1996-01-29	2012-03-15	Us Of America Represented By The Secretary Dept Of Health And Human Services	Dihydropyridin-pyridin-, benzopyranon- und triazolochinazolin-derivate, deren herstellung und verwendung als adenosinrezeptor-antagonisten
JPH10324687A (ja)	1997-02-19	1998-12-08	Nippon Soda Co Ltd	ピロール化合物、製法および農園芸用殺菌剤
US6191280B1 (en)	1997-05-30	2001-02-20	Basf Aktiengesellschaft	Method for producing substituted thiopyridines
CA2294830A1 (fr)	1997-07-16	1999-01-28	John Bondo Hansen	Derives de 1,2,4-thiadiazine fusionnee, leur preparation et utilisation
US6632823B1 (en)	1997-12-22	2003-10-14	Merck & Co., Inc.	Substituted pyridine compounds useful as modulators of acetylcholine receptors
DE19834044A1 (de)	1998-07-29	2000-02-03	Bayer Ag	Neue substituierte Pyrazolderivate
DE19834047A1 (de)	1998-07-29	2000-02-03	Bayer Ag	Substituierte Pyrazolderivate
DE19943635A1 (de)	1999-09-13	2001-03-15	Bayer Ag	Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943639A1 (de)	1999-09-13	2001-03-15	Bayer Ag	Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
DE19943636A1 (de)	1999-09-13	2001-03-15	Bayer Ag	Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943634A1 (de)	1999-09-13	2001-04-12	Bayer Ag	Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19947154A1 (de)	1999-10-01	2001-10-04	Bayer Ag	Substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
WO2001062233A2 (fr)	2000-02-25	2001-08-30	F. Hoffmann La Roche Ag	Modulateurs de recepteurs de l'adenosine
KR20030026979A (ko)	2000-07-18	2003-04-03	야마노우치세이야쿠 가부시키가이샤	디시아노피리딘 유도체를 포함하는 의약
AR031176A1 (es)	2000-11-22	2003-09-10	Bayer Ag	Nuevos derivados de pirazolpiridina sustituidos con piridina
WO2002048115A2 (fr)	2000-12-11	2002-06-20	E. I. Du Pont De Nemours And Company	Quinazolinones et pyridinylpyrimidinones pour la regulation de nuisibles invertebres
EP1347971B1 (fr)	2000-12-21	2006-03-01	Bristol-Myers Squibb Company	Inhibiteurs thiazolyl des tyrosine kinases de la famille tec
DE10110438A1 (de)	2001-03-05	2002-09-19	Bayer Ag	Substituierte 2-Oxy-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
DE10110750A1 (de)	2001-03-07	2002-09-12	Bayer Ag	Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE10110749A1 (de)	2001-03-07	2002-09-12	Bayer Ag	Substituierte Aminodicarbonsäurederivate
DE10110747A1 (de)	2001-03-07	2002-09-12	Bayer Ag	Substituierte 2,6-Diamino-3,5-dicyano-4-aryl-pyridine und ihre Verwendung
DE10110754A1 (de)	2001-03-07	2002-09-19	Bayer Ag	Substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
DE10115945A1 (de)	2001-03-30	2002-10-02	Bayer Ag	Substituierte 2-Carba-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
DE10115922A1 (de)	2001-03-30	2002-10-10	Bayer Ag	Cyclisch substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
DE10134481A1 (de)	2001-07-16	2003-01-30	Bayer Ag	Substituierte 2-Thio-3,5-dicyano-4-phenyl-6-aminopyridine und ihre Verwendung
DE10238113A1 (de)	2001-12-11	2003-06-18	Bayer Ag	Substituierte 2-Thio-3,5-dicyano-4-phenyl-6-aminopyridine und ihre Verwendung
JP2003183254A (ja)	2001-12-20	2003-07-03	Yamanouchi Pharmaceut Co Ltd	２−アシルアミノ−３，５−ジシアノピリジン誘導体又はその塩
AU2003237121A1 (en)	2002-04-26	2003-11-10	Vertex Pharmaceuticals Incorporated	Pyrrole derivatives as inhibitors of erk2 and uses thereof
DE10220570A1 (de)	2002-05-08	2003-11-20	Bayer Ag	Carbamat-substituierte Pyrazolopyridine
CN1309726C (zh) *	2002-08-02	2007-04-11	陶氏环球技术公司	含有4－芳基取代的三环茚基衍生物的第4族金属配合物
EP1388342A1 (fr)	2002-08-07	2004-02-11	Aventis Pharma Deutschland GmbH	Dérivés de cycloalkenylamine condensé avec un hététoaryle et acylé et leur utilisation comme produits pharmaceutiques
WO2004014368A1 (fr)	2002-08-12	2004-02-19	Sugen, Inc.	3-pyrrolyl-pyridopyrazoles et 3-pyrrolyl-indazoles utilises en tant que nouveaux inhibiteurs de la proteine kinase
WO2004054505A2 (fr)	2002-12-12	2004-07-01	Pharmacia Corporation	Procede d'utilisation de composes d'aminocyanopyridine en tant qu'inhibiteurs de la proteine mapkap kinase-2
AR042667A1 (es)	2002-12-26	2005-06-29	Taisho Pharmaceutical Co Ltd	Derivados de pirrolopirimidina y pirrolopiridina sustituidos con un grupo amino ciclico
TW200418829A (en)	2003-02-14	2004-10-01	Avanir Pharmaceutics	Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
AR045047A1 (es)	2003-07-11	2005-10-12	Arena Pharm Inc	Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
CN1856307A (zh)	2003-09-23	2006-11-01	默克公司	喹啉钾通道抑制剂
CA2545258A1 (fr)	2003-11-10	2005-05-26	Synta Pharmaceuticals, Corp.	Composes pyridiniques
US20050182105A1 (en)	2004-02-04	2005-08-18	Nirschl Alexandra A.	Method of using 3-cyano-4-arylpyridine derivatives as modulators of androgen receptor function
JP2007161585A (ja)	2004-06-25	2007-06-28	Taisho Pharmaceut Co Ltd	環状アミノ基で置換されているピロロピリミジン及びピロロピリジン誘導体
EP1781652A1 (fr)	2004-06-25	2007-05-09	Taisho Pharmaceutical Co., Ltd	Derives de pyrrolopyrimidine et de pyrrolopyridine substitues avec de la tetrahydropyridine comme antagonistes du crf
DE102004032651A1 (de)	2004-07-06	2006-02-16	Bayer Healthcare Ag	Verwendung von substituierten 2-Thio-3,5-dicyano-4-phenyl-6-aminopyriden bei der Behandlung von Übelkeit und Erbrechen
DE102004042607A1 (de)	2004-09-03	2006-03-09	Bayer Healthcare Ag	Substituierte Phenylaminothiazole und ihre Verwendung
EP2316457A1 (fr)	2004-09-20	2011-05-04	Xenon Pharmaceuticals Inc.	Dérivés de pyridazine destinés à l'inhibition de la stearoyl-coa-desaturase humaine
WO2006099958A1 (fr)	2005-03-24	2006-09-28	Bayer Healthcare Ag	Utilisation de 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines substituees pour traiter les lesions de reperfusion et les dommages de reperfusion
US7750015B2 (en)	2005-05-17	2010-07-06	Schering Corporation	Nitrogen-containing heterocyclic compounds and methods of use thereof
WO2007073855A1 (fr)	2005-12-23	2007-07-05	Bayer Healthcare Ag	Utilisation d’agonistes des recepteurs a1 de l’adenosine en vue de proteger les cellules renales contre les effets toxiques induits par des aminoglycosides au cours du traitement de maladies infectieuses
DE102006009813A1 (de)	2006-03-01	2007-09-06	Bayer Healthcare Ag	Verwendung von A2b/A1 Rezeptor Agonisten zur Modulation der Lipidspiegel
WO2007124546A1 (fr)	2006-04-28	2007-11-08	Avexa Limited	Inhibiteurs de l'intégrase-3
WO2008008059A1 (fr)	2006-07-12	2008-01-17	Locus Pharmaceuticals, Inc.	Agents anti-cancer et leurs utilisations
DE102006042143A1 (de)	2006-09-08	2008-03-27	Bayer Healthcare Aktiengesellschaft	Neue substituierte Bipyridin-Derivate und ihre Verwendung
DE102006056739A1 (de)	2006-12-01	2008-06-05	Bayer Healthcare Ag	Substituierte 4-Amino-3,5-dicyano-2-thiopyridine und ihre Verwendung
DE102006056740A1 (de)	2006-12-01	2008-06-05	Bayer Healthcare Ag	Cyclisch substituierte 3,5-Dicyano-2-thiopyridine und ihre Verwendung
DE102007035367A1 (de) *	2007-07-27	2009-01-29	Bayer Healthcare Ag	Substituierte Aryloxazole und ihre Verwendung
DE102007036075A1 (de)	2007-08-01	2009-02-05	Bayer Healthcare Ag	Prodrugs und ihre Verwendung
DE102007036076A1 (de)	2007-08-01	2009-02-05	Bayer Healthcare Aktiengesellschaft	Dipeptoid-Produgs und ihre Verwendung
DE102007061763A1 (de) *	2007-12-20	2009-06-25	Bayer Healthcare Ag	Substituierte azabicyclische Verbindungen und ihre Verwendung
DE102008008838A1 (de)	2008-02-13	2009-08-20	Bayer Healthcare Ag	Cycloalkoxy-substituierte 4-Phenyl-3,5-dicyanopyridine und ihre Verwendung
DE102008013587A1 (de)	2008-03-11	2009-09-17	Bayer Schering Pharma Aktiengesellschaft	Heteroaryl-substituierte Dicyanopyridine und ihre Verwendung
JP2011520997A (ja)	2008-05-29	2011-07-21	バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト	２−アルコキシ置換ジシアノピリジン類およびそれらの使用
DE102008062567A1 (de)	2008-12-16	2010-06-17	Bayer Schering Pharma Aktiengesellschaft	Dipeptoid-Prodrugs und ihre Verwendung
DE102008062566A1 (de)	2008-12-16	2010-06-17	Bayer Schering Pharma Aktiengesellschaft	Aminosäureester-Prodrugs und ihre Verwendung
DE102009006602A1 (de) *	2009-01-29	2010-08-05	Bayer Schering Pharma Aktiengesellschaft	Alkylamino-substituierte Dicyanopyridine und deren Aminosäureester-Prodrugs
RS54378B1 (sr)	2009-05-01	2016-04-28	Inotek Pharmaceuticals Corporation	Postupak smanjenja očnog pritiska kod ljudi

2009
- 2009-01-29 DE DE102009006602A patent/DE102009006602A1/de not_active Withdrawn
2010
- 2010-01-19 KR KR1020117017725A patent/KR101717305B1/ko not_active Expired - Fee Related
- 2010-01-19 PE PE2011001362A patent/PE20120430A1/es active IP Right Grant
- 2010-01-19 ES ES14155583.9T patent/ES2614702T3/es active Active
- 2010-01-19 SG SG2011050770A patent/SG172968A1/en unknown
- 2010-01-19 SI SI201030685T patent/SI2391620T1/sl unknown
- 2010-01-19 KR KR1020177006269A patent/KR101833188B1/ko not_active Expired - Fee Related
- 2010-01-19 PE PE2015000329A patent/PE20150636A1/es not_active Application Discontinuation
- 2010-01-19 PL PL10700508T patent/PL2391620T3/pl unknown
- 2010-01-19 NZ NZ594267A patent/NZ594267A/xx not_active IP Right Cessation
- 2010-01-19 DK DK10700508.4T patent/DK2391620T3/da active
- 2010-01-19 AU AU2010207786A patent/AU2010207786B2/en not_active Ceased
- 2010-01-19 WO PCT/EP2010/000262 patent/WO2010086101A1/fr not_active Ceased
- 2010-01-19 PT PT107005084T patent/PT2391620E/pt unknown
- 2010-01-19 ES ES10700508.4T patent/ES2473966T3/es active Active
- 2010-01-19 SI SI201031393A patent/SI2743270T1/sl unknown
- 2010-01-19 MX MX2011007800A patent/MX2011007800A/es active IP Right Grant
- 2010-01-19 EP EP10700508.4A patent/EP2391620B1/fr active Active
- 2010-01-19 MA MA34060A patent/MA33000B1/fr unknown
- 2010-01-19 EA EA201101111A patent/EA019275B1/ru not_active IP Right Cessation
- 2010-01-19 PL PL14155583T patent/PL2743270T3/pl unknown
- 2010-01-19 CN CN201510167727.3A patent/CN104844687B/zh not_active Expired - Fee Related
- 2010-01-19 PT PT141555839T patent/PT2743270T/pt unknown
- 2010-01-19 JP JP2011546673A patent/JP5693469B2/ja not_active Expired - Fee Related
- 2010-01-19 BR BRPI1007308A patent/BRPI1007308A2/pt not_active Application Discontinuation
- 2010-01-19 HR HRP20140714AT patent/HRP20140714T1/hr unknown
- 2010-01-19 CA CA2962039A patent/CA2962039A1/fr not_active Abandoned
- 2010-01-19 DK DK14155583.9T patent/DK2743270T3/en active
- 2010-01-19 UA UAA201110416A patent/UA104613C2/ru unknown
- 2010-01-19 HU HUE14155583A patent/HUE032008T2/en unknown
- 2010-01-19 CA CA2750769A patent/CA2750769C/fr not_active Expired - Fee Related
- 2010-01-19 RS RS20140393A patent/RS53448B/sr unknown
- 2010-01-19 CN CN201080014887.XA patent/CN102388040B/zh not_active Expired - Fee Related
- 2010-01-19 LT LTEP14155583.9T patent/LT2743270T/lt unknown
- 2010-01-19 EP EP14155583.9A patent/EP2743270B1/fr active Active
- 2010-01-19 MY MYPI2011003521A patent/MY156434A/en unknown
- 2010-01-26 UY UY0001032393A patent/UY32393A/es not_active Application Discontinuation
- 2010-01-26 AR ARP100100173A patent/AR075050A1/es not_active Application Discontinuation
- 2010-01-28 JO JO201023A patent/JO2927B1/en active
- 2010-01-28 TW TW099102338A patent/TWI457126B/zh not_active IP Right Cessation
- 2010-01-28 TW TW103133417A patent/TWI511968B/zh not_active IP Right Cessation
- 2010-01-29 US US12/697,000 patent/US8420825B2/en not_active Expired - Fee Related
2011
- 2011-07-11 IL IL214019A patent/IL214019A0/en not_active IP Right Cessation
- 2011-07-25 HN HN2011002037A patent/HN2011002037A/es unknown
- 2011-07-25 CO CO11092821A patent/CO6400193A2/es not_active Application Discontinuation
- 2011-07-25 GT GT201100205A patent/GT201100205A/es unknown
- 2011-07-26 EC EC2011011235A patent/ECSP11011235A/es unknown
- 2011-07-27 DO DO2011000243A patent/DOP2011000243A/es unknown
- 2011-07-27 CR CR20110407A patent/CR20110407A/es unknown
- 2011-07-27 TN TN2011000370A patent/TN2011000370A1/fr unknown
- 2011-07-28 CU CU2011000153A patent/CU24037B1/es active IP Right Grant
2013
- 2013-03-13 US US13/801,484 patent/US8772498B2/en not_active Expired - Fee Related
2014
- 2014-06-17 US US14/306,781 patent/US20140296515A1/en not_active Abandoned
- 2014-08-01 CY CY20141100585T patent/CY1115403T1/el unknown
2015
- 2015-02-03 JP JP2015019616A patent/JP5908620B2/ja active Active
- 2015-12-10 HK HK15112176.4A patent/HK1211308A1/xx unknown
2017
- 2017-02-03 CY CY20171100159T patent/CY1118601T1/el unknown
- 2017-02-08 HR HRP20170206TT patent/HRP20170206T1/hr unknown

Also Published As

Publication number	Publication date
JP5908620B2 (ja)	2016-04-26
ECSP11011235A (es)	2011-10-31
HK1211308A1 (en)	2016-05-20
PL2391620T3 (pl)	2014-09-30
PT2743270T (pt)	2017-02-15
PT2391620E (pt)	2014-06-25
DK2743270T3 (en)	2017-02-20
JP2015120727A (ja)	2015-07-02
HK1168353A1 (en)	2012-12-28
JO2927B1 (en)	2015-09-15
PE20150636A1 (es)	2015-05-08
CY1115403T1 (el)	2017-01-04
PE20120430A1 (es)	2012-04-21
SG172968A1 (en)	2011-08-29
CN104844687B (zh)	2019-04-02
AU2010207786A1 (en)	2011-08-25
MX2011007800A (es)	2011-11-18
LT2743270T (lt)	2017-02-27
CU24037B1 (es)	2014-11-27
NZ594267A (en)	2013-09-27
CA2750769C (fr)	2018-08-21
HRP20140714T1 (hr)	2014-11-21
WO2010086101A1 (fr)	2010-08-05
ES2614702T3 (es)	2017-06-01
EA201101111A1 (ru)	2012-02-28
JP2012516290A (ja)	2012-07-19
DK2391620T3 (da)	2014-08-11
US20140296515A1 (en)	2014-10-02
AR075050A1 (es)	2011-03-02
PL2743270T3 (pl)	2017-04-28
KR101833188B1 (ko)	2018-02-27
HUE032008T2 (en)	2017-08-28
DE102009006602A1 (de)	2010-08-05
CO6400193A2 (es)	2012-03-15
EP2743270A1 (fr)	2014-06-18
UY32393A (es)	2010-08-31
EP2391620B1 (fr)	2014-05-07
US20130267700A1 (en)	2013-10-10
MY156434A (en)	2016-02-26
EA019275B1 (ru)	2014-02-28
SI2743270T1 (sl)	2017-03-31
TW201504235A (zh)	2015-02-01
DOP2011000243A (es)	2017-10-15
JP5693469B2 (ja)	2015-04-01
HRP20170206T1 (hr)	2017-04-07
US8420825B2 (en)	2013-04-16
CA2962039A1 (fr)	2010-08-05
KR20170029029A (ko)	2017-03-14
GT201100205A (es)	2013-08-21
IL214019A0 (en)	2011-08-31
CN102388040B (zh)	2015-05-13
KR20110108377A (ko)	2011-10-05
TW201039821A (en)	2010-11-16
SI2391620T1 (sl)	2014-08-29
CU20110153A7 (es)	2012-02-15
AU2010207786B2 (en)	2015-10-22
US20100197609A1 (en)	2010-08-05
RS53448B (sr)	2014-12-31
CA2750769A1 (fr)	2010-08-05
TWI511968B (zh)	2015-12-11
US8772498B2 (en)	2014-07-08
CR20110407A (es)	2012-01-02
BRPI1007308A2 (pt)	2016-02-10
TWI457126B (zh)	2014-10-21
UA104613C2 (en)	2014-02-25
HN2011002037A (es)	2013-12-02
CN104844687A (zh)	2015-08-19
EP2743270B1 (fr)	2016-12-21
KR101717305B1 (ko)	2017-03-16
ES2473966T3 (es)	2014-07-08
CN102388040A (zh)	2012-03-21
MA33000B1 (fr)	2012-01-02
EP2391620A1 (fr)	2011-12-07
CY1118601T1 (el)	2017-07-12

Publication	Publication Date	Title
TN2011000370A1 (en)	2013-03-27	Alkylamine-substituted dicyanopyridine and amino acid ester prodrugs thereof
PH12013501143A1 (en)	2013-07-08	Substituted 1-benzylcycloalkylcarboxlic acids and use thereof
MY164356A (en)	2017-12-15	Substituted 5-fluoro-1h-pyrazolopyridines and their use
TN2011000466A1 (en)	2013-03-27	Substituted 2-acetamido -5-aryl-1, 2, 4- triazolones and use thereof
TN2012000428A1 (en)	2014-01-30	Bisaryl-bonded aryltriazolones and use thereof
PH12016500216B1 (en)	2018-01-29	Stable pharmaceutical composition and methods of using same
IN2015KN00262A (fr)	2015-06-12
IN2012DN02805A (fr)	2015-07-24
TN2015000026A1 (en)	2016-06-29	Novel 5-aminotetrahydroquinoline-2-carboxylic acids and use thereof
MY159630A (en)	2017-01-13	Pharmaceutical composition comprising linagliptin and optionally a sglt2 inhibitor, and uses thereof
ZA201108305B (en)	2012-08-29	Novel p2x7r antagonists and their use
WO2010139979A3 (fr)	2011-05-05	Procédés d'élaboration de formes cristallines
TN2011000595A1 (en)	2013-05-24	Substituted piperidines
MY150931A (en)	2014-03-14	Substituted oxazolidinones and their use
IN2012DN00763A (fr)	2015-06-26
MX339361B (es)	2016-05-23	Derivados de alternano.
TN2011000596A1 (en)	2013-05-24	Substituted piperidines
MX2013002261A (es)	2013-05-22	N-fenetiltriazolonacetamidas sustituidas y su uso.
PL2247573T3 (pl)	2011-11-30	Sole kwasu węglowego i siarkowego estrów 3-(2,2,2-trimetylohydrazynio)propionianów, oraz ich zastosowanie do wytwarzania dihydratu 3-(2,2,2-trimetylohydrazynio)propionianu
TN2013000243A1 (en)	2014-11-10	Substituted 1-benzylcycloalkylcarboxlic acids and use thereof
AU2016219657A1 (en)	2016-09-15	Stable pharmaceutical composition and methods of using same
HK1196611A (en)	2014-12-19	Novel compounds as modulators of gpr-119